Anxiety and mood (대한불안의학회지)

Korean Academy of Anxiety Disorders (대한불안의학회)
권호 표지
DOI QR코드

DOI QR Code

A Case of a Depressed Patient With Progressive Supranuclear Palsy

우울증으로 내원한 진행성 핵상 마비 환자 1례

  • Seoyun Han (Department of Psychiatry, Myong-ji Hospital, Hanyang University College of Medicine) ;
  • Jhin Goo Chang (Department of Psychiatry, Myong-ji Hospital, Hanyang University College of Medicine) ;
  • Su Young Lee (Department of Psychiatry, Myong-ji Hospital, Hanyang University College of Medicine)
  • 한서윤 (한양대학교 의과대학 명지병원 정신건강의학교실) ;
  • 장진구 (한양대학교 의과대학 명지병원 정신건강의학교실) ;
  • 이수영 (한양대학교 의과대학 명지병원 정신건강의학교실)
  • Received : 2023.04.16
  • Accepted : 2023.10.25
  • Published : 2023.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

Progressive supranuclear palsy (PSP) is rare atypical Parkinsonism accompanied by various psycho-behavioural problems. In this case report, we describe the diagnostic and treatment progress of a 65-year-old PSP patient who visited the psychiatric clinic with a depressed mood and lumbar pain resulting in a suicide attempt. Over the course of 30 months of treatment, typical characteristics of PSP, such as postural instability, dyskinesia, cognitive dysfunction and supranuclear gaze palsy, became prominent, and magnetic resonance imaging and the F-18 FP-CIT positron emission tomography revealed midbrain atrophy and reduced dopamine uptake in the basal ganglia. When treating elderly patients with depression, parkinsonism symptoms such as gait disturbances, frequent falls, tremors, and rigidity should be closely examined.

Keywords

References

  1. Galts CPC, Bettio LEB, Jewett DC, Yang CC, Brocardo PS, Rodrigues ALS, et al. Depression in neurodegenerative diseases: Common mechanisms and current treatment options. Neurosci Biobehav Rev 2019;102:56-84.  https://doi.org/10.1016/j.neubiorev.2019.04.002
  2. Barer Y, Chodick G, Cohen R, Grabarnik-John M, Ye X, Zamudio J, et al. Epidemiology of Progressive Supranuclear Palsy: Real World Data from the Second Largest Health Plan in Israel. Brain Sci 2022;12. 
  3. Gerstenecker A, Duff K, Mast B, Litvan I, Group E-PS. Behavioral abnormalities in progressive supranuclear palsy. Psychiatry Res 2013;210:1205-1210.  https://doi.org/10.1016/j.psychres.2013.08.045
  4. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet 2021;397:2284-2303.  https://doi.org/10.1016/S0140-6736(21)00218-X
  5. Veilleux Carpentier A, McFarland NR. Progressive supranuclear palsy: current approach and challenges to diagnosis and treatment. Curr Opin Neurol 2023;36:309-316.  https://doi.org/10.1097/WCO.0000000000001163
  6. Mueller C, Hussl A, Krismer F, Heim B, Mahlknecht P, Nocker M, et al. The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. Parkinsonism Relat Disord 2018;54:90-94.  https://doi.org/10.1016/j.parkreldis.2018.04.005
  7. Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 2001;57:467-473.  https://doi.org/10.1212/WNL.57.3.467
  8. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol 2021;20:385-397.  https://doi.org/10.1016/S1474-4422(21)00030-2
  9. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.  https://doi.org/10.1212/WNL.47.1.1
  10. Kim WH, Lee YS, Jung SH, Choi HJ, Lee MJ, Kang MH, et al. Major depressive disorder preceding the onset of progressive supranuclear palsy. Psychiatry Investig 2009;6:112-114.  https://doi.org/10.4306/pi.2009.6.2.112
  11. Morgan JC, Ye X, Mellor JA, Golden KJ, Zamudio J, Chiodo LA, et al. Disease course and treatment patterns in progressive supranuclear palsy: A real-world study. J Neurol Sci 2021;421:117293. 
  12. Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord 2017;32:853-864.  https://doi.org/10.1002/mds.26987
  13. Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Hoglinger GU. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 2017;16:552-563.  https://doi.org/10.1016/S1474-4422(17)30157-6
  14. Stamelou M, Hoglinger G. A review of treatment options for progressive supranuclear palsy. CNS Drugs 2016;30:629-636.  https://doi.org/10.1007/s40263-016-0347-2
  15. Giagkou N, Stamelou M. Therapeutic management of the overlapping syndromes of atypical parkinsonism. CNS Drugs 2018;32:827-837. https://doi.org/10.1007/s40263-018-0551-3